{"id":"NCT00112359","sponsor":"Gilead Sciences","briefTitle":"International Safety and Efficacy Study of Aztreonam for Inhalation Solution (AZLI) in Cystic Fibrosis Patients With P. Aeruginosa","officialTitle":"A Phase 3, Double-Blind, Multicenter, Multinational, Randomized, Placebo-Controlled Trial Evaluating Aztreonam Lysinate for Inhalation in Cystic Fibrosis Patients With Pulmonary Pseudomonas Aeruginosa (AIR-CF1)","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2005-05","primaryCompletion":"2007-04","completion":"2007-04","firstPosted":"2005-06-02","resultsPosted":"2011-04-21","lastUpdate":"2011-04-21"},"enrollment":166,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Cystic Fibrosis"],"interventions":[{"type":"DRUG","name":"AZLI 75 mg three times a day (TID)","otherNames":[]},{"type":"DRUG","name":"Placebo three times a day (TID)","otherNames":[]}],"arms":[{"label":"Placebo three times a day (TID)","type":"PLACEBO_COMPARATOR"},{"label":"AZLI 75 mg three times a day (TID)","type":"EXPERIMENTAL"}],"summary":"The purpose of this study was to evaluate the safety and efficacy of a 28-day course of aztreonam for inhalation solution (AZLI) in patients with cystic fibrosis (CF) and lung infection due to Pseudomonas aeruginosa (PA).","primaryOutcome":{"measure":"Change in CFQ-R Respiratory Symptoms Scale (RSS) Score","timeFrame":"Day 0 to Day 28","effectByArm":[{"arm":"Placebo TID","deltaMin":-2.63,"sd":1.95},{"arm":"75 mg AZLI TID","deltaMin":7.08,"sd":1.98}],"pValues":[{"comp":"OG000 vs OG001","p":"0.0005"}]},"eligibility":{"minAge":"6 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":7,"exclusionCount":14},"locations":{"siteCount":53,"countries":["United States","Australia","Canada","New Zealand"]},"refs":{"pmids":["19420195"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":12,"n":84},"commonTop":["Cough","Productive cough","Nasal congestion","Pharyngolaryngeal pain","Headache"]}}